Abstract Release:

Abstracts will be released to registered meeting attendees on April 18, 2022 at 12:00 PM CDT.

Posters by Abstract Type:

Regular Abstracts: Poster Boards A1- E4
Case Reports: Poster Board E5
Trials in Progress Abstracts: Poster Boards F1- F4

Posters by Topic:

Basic Science: Poster Boards A5-B1
Imaging: Poster Board B2
Impact of COVID-19: Poster Boards B3-B4
Other: Poster Board E5
Patient-Reported Outcomes: Poster Boards A2, F1
Quality of Care and Quality Improvement: Poster Boards A3, B5
Real-world Evidence: Poster Boards A4, B6, C1-C5
Therapeutics: Poster Boards A1, D1-D4, F2-F3
Treatment Toxicities and Symptom Management: Poster Board D5
Tumor Biology, Biomarkers, and Pathology: Poster Boards E1-E4, F4

Poster Board A1
Abstract 1: Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: Results from a discontinued study arm of CheckMate 9ER
First author: Bernard Escudier

Poster Board A2
Abstract 2: Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey
First author: Cristiane Decat Bergerot
*1st Place Abstract Award

Poster Board A3
Abstract 3: A systematic review of heterogeneity in outcome reporting, definition and measurement in localised kidney cancer
First author: Katharina Beyer
*2nd Place Abstract Award

Poster Board A4
Abstract 4: ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)
First author: Will Ince
*3rd Place Abstract Award

Poster Board A5
Abstract 5: SETD2 loss in kidney cancer – Setting the stage for synthetic lethality
First author: Aguirre A. de Cubas

Poster Board B1
Abstract 7: New Evidence of Preventing Kidney Tumor Progression in Pre-clinical Mouse Model
First author: Samy Lewiz Habib

Poster Board B2
Abstract 8: PSMA-expression in renal cell carcinoma as basis for theranostic approaches – an immunohistochemical nephrectomy study
First author: Lena M. Unterrainer

Poster Board B3
Abstract 9: Perceptions of COVID-19 vaccination in patients with renal cell carcinoma (RCC)
First author: Zeynep B. Zengin

Poster Board B4
Abstract 10: Waning efficacy of COVID-19 vaccination at 6 months in patients with renal cell carcinoma (RCC)
First author: Jasnoor Malhotra

Poster Board B5
Abstract 11: Retention in clinical trials: the kidney cancer patient perspective
First author: Josefine Björkqvist

Poster Board B6
Abstract 12: Efficacy of frontline combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)
First author: Lucia Carril-Ajuria

Poster Board C1
Abstract 13: Complete Responses with first line (1L) antiangiogenic monotherapy in Spanish patients with metastatic renal cell carcinoma (mRCC). The ATILA study
First author: Teresa Alonso-Gordoa

Poster Board C2
Abstract 14: Real-World Clinical Outcomes of tivozanib as first-line treatment of metastatic renal cell carcinoma in Germany
First author: Viktor Grünwald

Poster Board C3
Abstract 15: Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma.
First author: Severin Rodler

Poster Board C4
Abstract 16: Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT
First author: Peter J. Goebell

Poster Board C5
Abstract 17: Real-world clinical characteristics and treatment patterns in patients with advanced renal cell carcinoma treated with first-line immunotherapy + axitinib in Germany
First author: Giovanni Zanotti

Poster Board D1
Abstract 18: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (aRCC): Subsequent Therapy and Survival Outcomes with Lenvatinib (L) + Everolimus (E) vs Sunitinib (S)
First author: Thomas E. Hutson

Poster Board D2
Abstract 19: From cytokine to immunotherapy: Improvements in overall survival in metastatic renal cell carcinoma in a real-life population in Austria upon 3 decades of follow-up
First author: Dominik A. Barth

Poster Board D3
Abstract 20: Profile of Dissociated response in metastatic Clear Cell Renal Cell Carcinoma and subsequent radical therapy
First author: Mohamed Amine Tenabene

Poster Board D4
Abstract 21: AB521 is a Novel and Potent Clinical-stage HIF-2α Inhibitor for the Treatment of Renal Cell Carcinoma
First author: Kelsey E. Gauthier

Poster Board D5
Abstract 22: Characterization and Management of Adverse Reactions in Patients With Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study)
First author: Robert J. Motzer

Poster Board E1
Abstract 23: Relationship between circulating immune markers and tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab within the NIVOREN study.
First author: Lucia Carril-Ajuria

Poster Board E2
Abstract 24: Circulating microRNAs and treatment response to cabozantinib in metastatic clear cell renal cell carcinoma (mRCC) patients treated in the phase II CABOPRE trial.
First author: Lucia Carril-Ajuria

Poster Board E3
Abstract 25: Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
First author: Alexander Chehrazi-Raffle

Poster Board E4
Abstract 26: Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature
First author: Louise Geertsen

Poster Board E5
Abstract 27: Renal cell carcinoma in a patient with Situs Inversus Totalis – Laparoscopic radical nephrectomy is a safe and feasible option: A case report
First author: Benjamin Buckland

Poster Board F1
Abstract 28: A Three-Arm Randomized Multicenter Phase II Trial Comparing Patient-Reported Outcome (PRO) Monitoring  in Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma:  ePRO vs paper-PRO, or usual care (Trial in Progress)
First author: Takahiro Osawa

Poster Board F2
Abstract 29: LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
First author: Robert J. Motzer

Poster Board F3
Abstract 30: Trial in Progress: Individualized Treatment Strategy for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma – the INDIGO phase II study
First author: Ida Marie Lind Rasmussen

Poster Board F4
Abstract 31: AURORAX-0087A: Glycosaminoglycan (GAG) scores for recurrence detection in Leibovich Points ≥5 clear cell renal cell carcinoma – Trial In Progress
First author: Saeed Dabestani